ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...
Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...
Little more than a year after starting a business based on spontaneous tumor models in mice, GenPath Pharmaceuticals Inc. raised $42.7 million in a Series B financing. (BioWorld Today) ...
Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, ...
GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $42.7 million in series B funding. Flagship Ventures led the round, which included Highland Capital Partners, Oxford Biosciences, existing ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge-based GenPath Pharmaceuticals Inc., a company ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. GenPath Pharmaceuticals Inc. has changed its corporate name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results